Clinical Trial Update: Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating AGN-151607-DP in adults undergoing open ventral hernia repair to assess adverse events and changes in disease activity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ventral Hernia

Drugs mentioned

• AGN-151607-DP

Snippet

Sponsor: AbbVie | Conditions: Ventral Hernia | Phase 2 | Status: RECRUITING